首页> 外文期刊>Synthetic and Systems Biotechnology >Engineering metabolic pathways in Amycolatopsis japonicum for the optimization of the precursor supply for heterologous brasilicardin congeners production
【24h】

Engineering metabolic pathways in Amycolatopsis japonicum for the optimization of the precursor supply for heterologous brasilicardin congeners production

机译:工程化日本扁桃中的代谢途径,以优化异源油菜豆素同源物生产的前体供应

获取原文
获取外文期刊封面目录资料

摘要

The isoprenoid brasilicardin A is a promising immunosuppressant compound with a unique mode of action, high potency and reduced toxicity compared to today's standard drugs. However, production of brasilicardin has been hampered since the producer strain Nocardia terpenica IFM0406 synthesizes brasilicardin in only low amounts and is a biosafety level 2 organism. Previously, we were able to heterologously express the brasilicardin gene cluster in the nocardioform actinomycete Amycolatopsis japonicum. Four brasilicardin congeners, intermediates of the BraA biosynthesis, were produced. Since chemical synthesis of the brasilicardin core structure has remained elusive we intended to produce high amounts of the brasilicardin backbone for semi synthesis and derivatization. Therefore, we used a metabolic engineering approach to increase heterologous production of brasilicardin in A.?japonicum . Simultaneous heterologous expression of genes encoding the MVA pathway and expression of diterpenoid specific prenyltransferases were used to increase the provision of the isoprenoid precursor isopentenyl diphosphate (IPP) and to channel the precursor into the direction of diterpenoid biosynthesis. Both approaches contributed to an elevated heterologous production of the brasilicardin backbone, which can now be used as a starting point for semi synthesis of new brasilicardin congeners with better properties.
机译:与当今的标准药物相比,类异戊二烯类巴西ilicardin A是一种有前途的免疫抑制剂,具有独特的作用方式,高效能和降低的毒性。但是,由于生产菌株Nocardia terpenica IFM0406只能合成少量的巴西ilicardin,并且是生物安全等级2的生物,因此巴西利亚cardin的生产受到了阻碍。以前,我们能够在nocardioform放线菌Amycolatopsis japonicum中异源表达brasilicardin基因簇。产生了四种Brasilicardin同源物,它们是BraA生物合成的中间体。由于巴西利卡汀核心结构的化学合成仍然难以实现,因此我们打算生产大量的巴西利卡汀骨架以进行半合成和衍生化。因此,我们使用了一种代谢工程方法来增加日本根茎中巴西ilicardin的异源生产。编码MVA途径的基因和二萜类异戊二烯基异戊二烯基转移酶的同时异源表达用于增加类异戊二烯前体异戊烯基二磷酸酯(IPP)的提供并将前体引导至二萜生物合成的方向。两种方法都促进了巴西雷卡德主链的异源生产增加,现在可以用作半合成具有更好性能的新型巴西雷卡德同系物的起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号